Cargando…
CAMK2G is identified as a novel therapeutic target for myelofibrosis
Although JAK1/2 inhibition is effective in alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here, we established induced pluripotent stem cells (iPSCs) derived from MF patient s...
Autores principales: | Miyauchi, Masashi, Sasaki, Ken, Kagoya, Yuki, Taoka, Kazuki, Masamoto, Yosuke, Yamazaki, Sho, Arai, Shunya, Mizuno, Hideaki, Kurokawa, Mineo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905705/ https://www.ncbi.nlm.nih.gov/pubmed/34521112 http://dx.doi.org/10.1182/bloodadvances.2020003303 |
Ejemplares similares
-
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
por: Masamoto, Yosuke, et al.
Publicado: (2022) -
Patient-specific comorbidities as prognostic variables for survival in myelofibrosis
por: Sochacki, Andrew L., et al.
Publicado: (2022) -
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
por: Dunbar, Andrew J., et al.
Publicado: (2023) -
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes
por: Sunami, Yoshitaka, et al.
Publicado: (2022) -
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
por: Tanaka, Atsushi, et al.
Publicado: (2022)